Table 2.
The percentage of patients in the PreCARA cohort using certain medication during pregnancy (total number of patients=184)
| Medication | Last visit before pregnancy n (%) N=116 |
1st trimester visit n (%) N=167 |
2nd trimester visit n (%) N=174 |
3rd trimester visit n (%) N=172 |
6 weeks postpartum visit n (%) N=170 |
12 weeks postpartum visit n (%) N=153 |
26 weeks postpartum visit n (%) N=125 |
| Methotrexate | 2 (1.7) | 0 | 0 | 0 | 27 (15.9) | 34 (22.2) | 31 (24.8) |
| Leflunomide | 0 | 0 | 0 | 0 | 1 (0.6) | 2 (1.3) | 3 (2.4) |
| Hydroxychloroquine | 77 (66.4) | 96 (57.5) | 94 (54.0) | 93 (54.1) | 97 (57.1) | 88 (57.5) | 70 (56.0) |
| Sulfasalazine | 76 (65.6) | 103 (61.7) | 104 (59.8) | 103 (59.8) | 104 (61.2) | 95 (62.1) | 79 (63.2) |
| Prednisone | 53 (45.7) | 69 (41.3) | 67 (38.5) | 72 (41.9) | 67 (39.4) | 60 (39.2) | 46 (36.8) |
| Azathioprine | 1 (0.9) | 3 (1.8) | 3 (1.7) | 3 (1.7) | 1 (0.6) | 2 (1.3) | 1 (0.8) |
| Certolizumab pegol | 31 (26.7) | 38 (22.8) | 48 (27.6) | 50 (29.1) | 47 (27.7) | 46 (30.1) | 38 (30.4) |
| Adalimumab | 8 (6.9) | 8 (4.8) | 0 | 0 | 5 (2.9) | 6 (3.9) | 7 (5.6) |
| Etanercept | 19 (16.4) | 20 (12.0) | 19 (10.9) | 6 (3.5) | 19 (11.2) | 22 (14.4) | 16 (12.8) |
| Infliximab | 11 (9.5) | 11 (6.6) | 4 (2.3) | 0 | 1 (0.6) | 2 (1.3) | 1 (0.8) |
| Tocilizumab | 2 (1.7) | 0 | 0 | 0 | 4 (2.4) | 4 (2.6) | 6 (4.8) |
| Golimumab | 0 | 0 | 0 | 0 | 0 | 0 | 1 (0.8) |
| Abatacept | 0 | 0 | 0 | 0 | 1 (0.6) | 2 (1.3) | 2 (1.6) |